filmov
tv
Key Points about MET in Lung Cancer
Показать описание
This video was recorded before the February 2021 approval of tepotinib for exon-14 skipping in MET.
Dr. Justin Gainor discusses what patients need to know about the MET biomarker in lung cancer.
Support for this educational program provided by Amgen, AstraZeneca, Blueprint Medicines, Bristol Myers Squibb, Genentech, Lilly Oncology, Merck, Novartis and Pfizer.
Dr. Justin Gainor discusses what patients need to know about the MET biomarker in lung cancer.
Support for this educational program provided by Amgen, AstraZeneca, Blueprint Medicines, Bristol Myers Squibb, Genentech, Lilly Oncology, Merck, Novartis and Pfizer.
0:02:47
0:00:20
0:00:26
0:00:27
0:00:27
0:00:43
0:00:58
0:00:14
0:00:40
0:00:30
0:00:41
0:00:27
0:00:29
0:00:31
0:00:24
0:00:13
0:00:17
0:00:29
0:00:17
0:00:27
0:00:15
0:00:28
0:00:16
0:00:24